Adam Pluzanski
Overview
Explore the profile of Adam Pluzanski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
7796
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peters S, Paz-Ares L, Reck M, Carbone D, Brahmer J, Borghaei H, et al.
J Thorac Oncol
. 2024 Oct;
20(1):94-108.
PMID: 39369790
Introduction: Nivolumab plus ipilimumab-based treatment regimens have shown long-term, durable efficacy benefits in patients with metastatic NSCLC. Here we report clinical outcomes from a pooled analysis of patients with metastatic...
2.
Pu X, Li J, Zhang B, Zhang J, Mok T, Nakagawa K, et al.
Future Oncol
. 2024 Oct;
20(37):2971-2982.
PMID: 39360943
We investigated association between skin adverse events (AEs) and efficacy with dacomitinib in patients with -positive non-small-cell lung cancer (NSCLC). analyses from ARCHER 1050 evaluated efficacy in patients who did...
3.
Piorek A, Pluzanski A, Knetki-Wroblewska M, Winiarczyk K, Tabor S, Kowalski D, et al.
Oncol Rev
. 2024 Oct;
18:1451247.
PMID: 39360235
A substantial portion of patients with advanced cancer cannot be cured, regardless of the therapeutic methods employed. Hence, rational palliative causal treatment becomes crucial. Representative studies specifically addressing the exclusive...
4.
Janzic U, Maimon Rabinovich N, Shalata W, Kian W, Szymczak K, Dziadziuszko R, et al.
Curr Oncol
. 2024 Aug;
31(8):4369-4381.
PMID: 39195309
ROS1 rearrangements are considered rare in non-small-cell lung cancer (NSCLC). This retrospective real-world study aimed to evaluate first-line treatment with crizotinib, a tyrosine kinase inhibitor (TKI) standard of care vs....
5.
Piorek A, Pluzanski A, Wisniewski P, Tabor S, Winiarczyk K, Knetki-Wroblewska M, et al.
Diseases
. 2024 Aug;
12(8).
PMID: 39195180
Pulmonary benign metastasizing leiomyoma (PBML) is a rare condition characterized by the spread of uterine leiomyomas to the lungs, typically observed in premenopausal women with a history of hysterectomy or...
6.
Piorek A, Pluzanski A, Knetki-Wroblewska M, Winiarczyk K, Tabor S, Teterycz P, et al.
BMC Cancer
. 2024 Jun;
24(1):686.
PMID: 38840114
Objective: Primary tracheal tumors are very rare and their management is not definitely established. Due to its rarity, providing patient care in terms of optimal management poses a considerable challenge....
7.
Piorek A, Pluzanski A, Teterycz P, Tabor S, Winiarczyk K, Knetki-Wroblewska M, et al.
Thorac Cancer
. 2024 Mar;
15(11):878-883.
PMID: 38429910
Background: Primary tracheal tumors are very rare and the literature on this subject is limited. The most common histological type of primary tracheal tumors is squamous cell carcinoma (SCC), followed...
8.
Janzic U, Shalata W, Szymczak K, Dziadziuszko R, Jakopovic M, Mountzios G, et al.
Int J Mol Sci
. 2023 Aug;
24(16).
PMID: 37629023
BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in these cases for the first and second line is not clear. An international registry was...
9.
Reck M, Ciuleanu T, Lee J, Schenker M, Zurawski B, Kim S, et al.
J Thorac Oncol
. 2023 May;
18(8):1055-1069.
PMID: 37146754
Introduction: In CheckMate 227 Part 1, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with metastatic NSCLC, regardless of tumor programmed death-ligand 1 (PD-L1) expression. Here, we...
10.
Knetki-Wroblewska M, Tabor S, Piorek A, Pluzanski A, Winiarczyk K, Zaborowska-Szmit M, et al.
J Clin Med
. 2023 Mar;
12(6).
PMID: 36983409
Background: The efficacy of nivolumab and atezolizumab in advanced pre-treated NSCLC was documented in prospective trials. We aim to confirm the benefits and indicate predictive factors for immunotherapy in daily...